PsA Til Death Do Us Part (1.20.2023)
Dr. Jack Cush reviews the highlights from the past week on RheumNow.com.
Read ArticleLinks:
Links:
Links:
Links:
Links:
Dr. Jack Cush reviews the highlights from the past week on RheumNow.com.
Read ArticleInflammatory disorders are often accompanied by an increased mortality risk, either from secondary malignancy, infection or cardiovascular disease. A recent meta-analysis showed a significantly increased risk of overall mortality in ankylosing spondylitis (AS) but not psoriatic arthritis (PsA
Read ArticleBimekizumab, an investigational biologic drug targeting interleukin (IL)-17A/F, appeared highly effective in patients with axial spondyloarthritis (axSpA), researchers said.
Read ArticleLinks:
Links:
Dr. Jack Cush reviews the notable standouts in the news since the 1st of January. Surprising reports on ferritin, alcohol benefits, cannabis for pain and a lower dementia risk with hydroxychloroquine. Here are the links below.
ACR GCA classification criteria tested in 676
Links:
Links:
2022 was a year of recovery, discovery, and some losses. While still dealing with the aftermath of COVID-19, rheumatologists were resilient as leaders for their patients and research in advancing rheumatologic care.
Read ArticleLinks:
Dr. Jack Cush reviews the top abstracts from EULAR 2022 As chosen by me with the aid of the RheumNow EULAR faculty. “Top” is relative and subjective, but my criteria for inclusion are based on impact, water cooler talk potential, innovation and social media buzz. Speaking of social media…
Read ArticleLinks:
Links:
Links:
Dr. Jack Frost reviews the news, and journal articles from the past week on RheumNow and ends with an audience question on "Macro-CK".
During 2021–22 FLU season, 6% of hosp pedi-influenza pts had SARS-CoV-2 coinfection; these required more respiratory support. Risk of
Links:
Links: